OBJECTIVE: To examine the implications of early virologic response to highly active antiretroviral therapy (HAART) on long-term HAART utilization patterns, development of diabetes or hyperlipidemia, and mortality in an urban HIV-1 clinic. DESIGN: A cohort of 444 patients in an urban HIV-1 clinic, who started HAART prior to January 1, 1999, were categorized by virologic response in the first 18 months of therapy: durable viral suppression, initial suppression followed by rebound, and failure to achieve suppression. Antiretroviral exposure, HIV-1 RNA levels, CD4 cell counts, development of diabetes or hyperlipidemia, and survival were compared in the three groups. RESULTS: Over 4 years of follow-up, patients in the durable suppression group used HAART 82% of the time compared with 60% in the rebound group (p <.001) and 23% in the failure to suppress group (p <.001). Through 4 years of follow-up, patients in the rebound group had a cumulative exposure to a median of seven antiretroviral drugs (interquartile range [IQR]: 6-9) compared with five drugs in the durable suppression group (IQR: 4-6) and five drugs in the failure to suppress group (IQR: 3-7) (p <.001 for both comparisons with the rebound group). At 5 years, the estimated proportions surviving were 89% in the durable suppression group, 76% in the rebound group (p =.04), and 56% in the failure to suppress group (p <.001). During follow-up, 35% in the durable suppression group developed diabetes or hyperlipidemia compared with 24% in the rebound group (p =.15) and 8% in the failure to suppress group (p <.001). CONCLUSIONS: This study highlights the long-term implications of early virologic response to HAART for survival, accumulation of triple-class antiretroviral exposure, and development of HAART-associated toxicities.
OBJECTIVE: To examine the implications of early virologic response to highly active antiretroviral therapy (HAART) on long-term HAART utilization patterns, development of diabetes or hyperlipidemia, and mortality in an urban HIV-1 clinic. DESIGN: A cohort of 444 patients in an urban HIV-1 clinic, who started HAART prior to January 1, 1999, were categorized by virologic response in the first 18 months of therapy: durable viral suppression, initial suppression followed by rebound, and failure to achieve suppression. Antiretroviral exposure, HIV-1 RNA levels, CD4 cell counts, development of diabetes or hyperlipidemia, and survival were compared in the three groups. RESULTS: Over 4 years of follow-up, patients in the durable suppression group used HAART 82% of the time compared with 60% in the rebound group (p <.001) and 23% in the failure to suppress group (p <.001). Through 4 years of follow-up, patients in the rebound group had a cumulative exposure to a median of seven antiretroviral drugs (interquartile range [IQR]: 6-9) compared with five drugs in the durable suppression group (IQR: 4-6) and five drugs in the failure to suppress group (IQR: 3-7) (p <.001 for both comparisons with the rebound group). At 5 years, the estimated proportions surviving were 89% in the durable suppression group, 76% in the rebound group (p =.04), and 56% in the failure to suppress group (p <.001). During follow-up, 35% in the durable suppression group developed diabetes or hyperlipidemia compared with 24% in the rebound group (p =.15) and 8% in the failure to suppress group (p <.001). CONCLUSIONS: This study highlights the long-term implications of early virologic response to HAART for survival, accumulation of triple-class antiretroviral exposure, and development of HAART-associated toxicities.
Authors: J Dzangare; E Gonese; O Mugurungi; T Shamu; T Apollo; D E Bennett; K F Kelley; M R Jordan; C Chakanyuka; F Cham; R M Banda Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian Journal: Clin Infect Dis Date: 2014-09-17 Impact factor: 9.079
Authors: M Zaccarelli; P Lorenzini; V Tozzi; F Forbici; F Ceccherini-Silberstein; C Gori; R D'Arrigo; M P Trotta; P Narciso; C F Perno; A Antinori Journal: Infection Date: 2009-03-09 Impact factor: 3.553
Authors: Amanda D Castel; Mariah M Kalmin; Rachel L D Hart; Heather A Young; Harlen Hays; Debra Benator; Princy Kumar; Richard Elion; David Parenti; Maria Elena Ruiz; Angela Wood; Lawrence D'Angelo; Natella Rakhmanina; Sohail Rana; Maya Bryant; Annick Hebou; Ricardo Fernández; Stephen Abbott; James Peterson; Kathy Wood; Thilakavathy Subramanian; Jeffrey Binkley; Lindsey Powers Happ; Michael Kharfen; Henry Masur; Alan E Greenberg Journal: AIDS Care Date: 2016-06-13
Authors: Andrew E Petroll; Wayne DiFranceisco; Timothy L McAuliffe; David W Seal; Jeffrey A Kelly; Steven D Pinkerton Journal: J Urban Health Date: 2008-12-09 Impact factor: 3.671
Authors: Catherine C McGowan; David D Weinstein; Charles P Samenow; Samuel E Stinnette; Gema Barkanic; Peter F Rebeiro; Timothy R Sterling; Richard D Moore; Todd Hulgan Journal: PLoS One Date: 2011-04-25 Impact factor: 3.240